Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.
STATE OF NEW YORK
________________________________________________________________________
6422
2025-2026 Regular Sessions
IN SENATE
March 13, 2025
___________
Introduced by Sen. HOYLMAN-SIGAL -- read twice and ordered printed, and
when printed to be committed to the Committee on Higher Education
AN ACT to amend the education law and the public health law, in relation
to prescription labels for mifepristone, misoprostol, gonadotropin-re-
leasing hormone agonists, pubertal suppressants, anabolic steroids,
alpha reductase inhibitors, progestins, or drug classes for hormone
replacement therapy for treatment of gender dysphoria
The People of the State of New York, represented in Senate and Assem-bly, do enact as follows:
1 Section 1. Paragraph b-1 of subdivision 1 of section 6807 of the
2 education law, as added by chapter 7 of the laws of 2025, is amended to
3 read as follows:
4 b-1. Notwithstanding paragraph b of this section, the prescription
5 label for mifepristone, misoprostol, [and their generic alternatives]
6 gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic
7 steroids, alpha reductase inhibitors, progestins, or drug classes for
8 hormone replacement therapy for treatment of gender dysphoria, may
9 include the name or address of the dispensing health care practice
10 instead of the name of the dispenser.
11 § 2. Subdivision 1-a of section 6810 of the education law, as added by
12 chapter 7 of the laws of 2025, is amended to read as follows:
13 1-a. Notwithstanding subdivision one of this section, at the
14 prescriber's request, the prescription label for mifepristone, misopros-
15 tol, [and their generic alternatives] gonadotropin-releasing hormone
16 agonists, pubertal suppressants, anabolic steroids, alpha reductase
17 inhibitors, progestins, or drug classes for hormone replacement therapy
18 for treatment of gender dysphoria, may include the name of the prescrib-
19 ing health care practice instead of the name of the prescriber.
20 § 3. The public health law is amended by adding a new section 280-d to
21 read as follows:
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[] is old law to be omitted.
LBD10852-01-5
S. 6422 2
1 § 280-d. Patient notification of prescription label change. A health
2 care prescriber shall inform the patient if such prescriber has included
3 or has requested to include the name or address of the prescribing
4 health care practice instead of the name of such prescriber on the
5 prescription label when prescribing mifepristone, misoprostol, gonado-
6 tropin-releasing hormone agonists, pubertal suppressants, anabolic ster-
7 oids, alpha reductase inhibitors, progestins, or drug classes for
8 hormone replacement therapy for treatment of gender dysphoria.
9 § 4. This act shall take effect immediately.
